[1] Luketic VA, Shiffman ML. Benign recurrent intrahepatic cholestasis. Clin Liver Dis, 2004,8:133-149.
[2] Summerskill WH, Walshe JM. Benign recurrent intrahepatic "obstructive" jaundice. Lancet,1959,2:686-690.
[3] Bull LN, van Eijk MJ, Pawlikowska L, et al. A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nat Genet,1998,18:219-224.
[4] Cai SY, Gautam S, Nguyen T, et al. ATP8B1 deficiency disrupts the bile canalicular membrane bilayer structure in hepatocytes, but FXR expression and activity are maintained. Gastroenterology,2009,136:1060-1069.
[5] Gonzales E, Jacquemin E. Mutation specific drug therapy for progressive familial or benign recurrent intrahepatic cholestasis: a new tool in a near future? J Hepatol,2010,53:385-387.
[6] van Mil SW, van der Woerd WL, van der Brugge G, et al. Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11. Gastroenterology,2004,127:379-384.
[7] Stapelbroek JM, van Erpecum KJ, Klomp LW, et al. Liver disease associated with canalicular transport defects: current and future therapies. J Hepatol,2010,52:258-271.
[8] van Dijk R, Kremer AE, Smit W, et al. Characterization and treatment of persistent hepatocellular secretory failure. Liver Int,2015,35:1478-1488.
[9] Beuers U. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol,2006,3:318-328.
[10] O?dakowska-Jedynak U, Jankowska I, Hartleb M, et al. Treatment of pruritus with Prometheus dialysis and absorption system in a patient with benign recurrent intrahepatic cholestasis. Hepatol Res,2014,44:E304-e308.
[11] Choudhury A, Kulkarni AV, Sahoo B, et al. Endoscopic nasobiliary drainage: an effective treatment option for benign recurrent intrahepatic cholestasis (BRIC). BMJ Case Rep,2017,2017:bcr2016218874..
[12] Van Itallie TB, Hashim SA, Crampton RS, et al. The treatment of pruritus and hypercholesteremia of primary biliary cirrhosis with cholestyramine. N Engl J Med, 1961,265:469-474.
[13] Datta DV, Sherlock S. Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis. Gastroenterology,1966,0:323-332.
[14] Carey JB Jr, Williams G. Relief of the pruritus of jaundice with a bile-acid sequestering resin. JAMA,1961,176:432-435.
[15] Jones EA, Bergasa NV. Evolving concepts of the pathogenesis and treatment of the pruritus of cholestasis. Can J Gastroenterol,2000,14:33-40.
[16] Bergasa NV, Thomas DA, Vergalla J, et al. Plasma from patients with the pruritus of cholestasis induces opioid receptor-mediated scratching in monkeys. Life Sci 1993,53:1253-1257.
[17] Shawcross DL, Jalan R. Delayed opioid withdrawal-like reaction in primary biliary cirrhosis following naloxone therapy. Gastroenterology,2001,121:743-744.
[18] Koukoulioti E, Ziagaki A, Weber SN, et al. Long-Term Colestyramine Treatment Prevents Cholestatic Attacks in Refractory Benign Recurrent Intrahepatic Cholestasis Type 1 Disease. Hepatology,2021,74:522-524.
[19] Uegaki S, Tanaka A, Mori Y, et al. Successful treatment with colestimide for a bout of cholestasis in a Japanese patient with benign recurrent intrahepatic cholestasis caused by ATP8B1 mutation. Intern Med,2008,47:599-602.
[20] Piazzolla M, Castellaneta N, Novelli A, et al. Nonsense variant of ATP8B1 gene in heterozygosis and benign recurrent intrahepatic cholestasis: A case report and review of literature. World J Hepatol,2020,12:64-71.
[21] al Drees K, al Zaben A, al Amir A, et al. Benign recurrent intrahepatic cholestasis in a Saudi child. Ann Trop Paediatr,1999,19:215-217.
[22] Bijleveld CM, Vonk RJ, Kuipers F, et al. Benign recurrent intrahepatic cholestasis: a long-term follow-up study of two patients. Hepatology,1989,9:532-537. |
